Cannabinoids: Potential targets for bladder dysfunction

Handbook of Experimental Pharmacology

Volumn 202, Issue , 2011, Pages 425-451

  Ruggieri Sr , Michael R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acrolein; Adenylyl cyclase; Bladder; Bladder contraction; Bladder spasticity; Cannabidiol; Cannabinoids; Cannabis; Capsazepine; Chemical cystitis; Cyclooxygenase; Cyclophosphamide; Endocannabinoids; Entourage lipids; G protein; Immunohistochemistry; In situ hybridization; Incontinence; Inflammation; Intravesical turpentine; Leukotrienes; Marijuana; Micturition; Micturition volume threshold; Multiple sclerosis; Nerve growth factor; Nocturia; Overactive bladder; Pain; Pontine micturition center; Resiniferatoxin; Urinary frequency; Urinary hesitance; Urinary tract; Urinary urgency

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 AMINOBUTYRIC ACID; ANANDAMIDE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; CHOLECYSTOKININ; NABILONE; NERVE GROWTH FACTOR; PALMIDROL; PLACEBO; VANILLOID RECEPTOR 1; ENDOCANNABINOID;

ARTICLE; BLADDER CONTRACTION; BLADDER DYSFUNCTION; CELLULAR DISTRIBUTION; CYSTALGIA; CYSTITIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SELECTIVITY; HIPPOCAMPUS; HUMAN; HYPERALGESIA; MICTURITION REFLEX; MULTIPLE SCLEROSIS; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; SPASTICITY; URINARY TRACT FUNCTION; URINARY URGENCY; ANIMAL; BLADDER; BLADDER DISEASE; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER DISEASES;

EID: 79952241103     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-16499-6_20     Document Type: Article

References (145)

1. Apodaca G, Balestreire E, Birder LA (2007) The uroepithelial-associated sensory web. Kidney Int 72(9): 1057-1064 (Pubitemid 47609034)
2. Ashton JC, Ashton JC (2007) Cannabinoids for the treatment of inflammation. Curr Opin Invest Drugs 8(5):373-384 (Pubitemid 46705390)
3. Ashton JC, Smith PF, Ashton JC, Smith PF (2007) Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol 5(3):175-185
4. Avelino A, Cruz C, Nagy I, Cruz F (2002) Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 109(4):787-798 (Pubitemid 34260863)
5. Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2(5):291-298
6. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271(17):9902-9905 (Pubitemid 26131542)
7. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z et al (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity, Eur J Pharmacol 353(1):23-31 (Pubitemid 28352285)
8. Birder LA, de Groat WC (1992) Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat. J Neurosci 12(12):4878-4889
9. Bodei S, Arrighi N, Spano P, Sigala S. Bodei S, Arrighi N et al (2009) Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol 379(4):413-415
10. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287(3):884-888 (Pubitemid 29131596)
11. Bowery NG, Hudson AL, Price GW (1987) GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 20(2):365-383 (Pubitemid 17048701)
12. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis, [see comment]. Mult Scler 10(4)425-433
13. Busch-Petersen J, Hill WA, Fan P, Khanolkar A, Xie XQ, Tius MA et al (1996) Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. J Med Chem 39(19):3790-3796 (Pubitemid 26307883)
14. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway, [see comment]. Nature 389 (6653):81.6-824
15. Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44-48 (Pubitemid 27283078)
16. Cox PJ (1979) Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 28(13):2045-2049
17. De Petrocellis L, Chu CJ, Moriello AS, Kellner JC, Walker JM, Di Marzo V et al (2004) Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol 143(2):251-256 (Pubitemid 39315145)
18. De Smet PA (1997) The role of plant-derived drugs and herbal medicines in healthcare. Drugs 54(6):801-840
19. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howie AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34(5):605-613
20. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. [see comment]. Science 258(5090): 1946-1949
21. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38(2): 151-178
22. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21 (1.2):521-528
23. [erratum appears in Trends Neurosci 1999 Feb;22(2):80]
24. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL et al (2001) Highly selective CB(I) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun 281(2):444-451
25. di Tomaso E, Beltramo M, Piomelli D (1996) Brain cannabinoids in chocolate. Nature 382 (6593):677-678 [see comment]
26. Dinh TP, Freund TF, Piomelli D, Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121 (1-2):149-158 (Pubitemid 36044549)
27. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I et al (2004a) Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24(50): 11253-11263 (Pubitemid 39658260)
28. Dinis P, Charrua A, Avelino A, Cruz F, Dinis P, Charrua A et al (2004b) Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU Int 94(1): 153-157 (Pubitemid 38980326)
29. Dmitrieva N, Shelton D, Rice AS, McMahon SB (1997) The role of nerve growth factor in a model of visceral inflammation. Neuroscience 78(2)449-459 (Pubitemid 27170336)
30. Dyson A, Peacock M, Chen A, Courade JP, Yaqoob M, Groarke A et al (2005) Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116(1-2): 129-137 (Pubitemid 40828508)
31. Egertova M, Elphick MR (2000) Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422(2): 159-171 (Pubitemid 30390161)
32. 1 receptor in rat brain. Proc R Soc Lond Ser B Biol Sci 265(1410):2081-2085
33. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92(8):3376-3380
34. Farquhar-Smith WP, Jaggar SI, Rice AS, Farquhar-Smith WP, Jaggar SI, Rice ASC (2002) Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97(1.-2): 11-21 (Pubitemid 34603305)
35. 2 receptors. Mol Pharmacol 48(3)443-450
36. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ et al (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284(1):291-297 (Pubitemid 28109558)
37. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V et al (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues, FEBS Lett 513(2-3):294-298
38. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J 17(6):636-641 (Pubitemid 44575283)
39. Fry CH, Byliss M, Pirolo JS, Ikeda Y, Hussain M (2010) The influence of age, gender and bladder dysfunction on the contractile properties of isolated human detrusor smooth muscle. BJU Int in press, first published online: 11 Nov 2010, doi: 10.1111/j.1464-41.0X.201.009845.x
40. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P et al (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232(1):54-61
41. Gallant M, Dufresme C, Girard Y, Gual D, Leblanc Y, Prasit P et al (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6(1.9):2263-2268 (Pubitemid 26328497)
42. Garcia MdC, Adler-Graschinsky E, Celuch SM (2009) Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur J Pharmacol 610(1-3):75-80
43. Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM et al (1996) Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors, Bioorg Med Chem Lett 6(2): 189-194 (Pubitemid 26045675)
44. Glass M, Dragunow M, Faull RL (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77(2):299-318 (Pubitemid 27079604)
45. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071(1):10-23 (Pubitemid 43255471)
46. Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P et al (2009) Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 181 (4): 1939-1948
47. Greenamyre JT, Young AB, Penney JB (1984) Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system. J Neurosci 4(8):2133-2144 (Pubitemid 14025574)
48. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM et al (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377(1):117-125 (Pubitemid 29322766)
49. Grotenhermen F, Grotenhermen F (2004) Pharmacology of cannabinoids. Neuroendocrinol Lett 25(1-2): 14-23 (Pubitemid 44783352)
50. Grotenhermen F, Grotenhermen F (2005) Cannabinoids. Curr Drug Targets CNS Neurol Disord 4(5):507-530 (Pubitemid 41448378)
51. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12 (9):3239-3249
52. Hamdani N, van der Velden J, Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379(4)403-407
53. [Erratum appears in Naunyn Schmiedebergs Arch Pharmacol, 2009 Jun;379(6):637]
54. Hanus L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36(20):3032-3034 (Pubitemid 23315410)
55. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96(25): 14228-14233 (Pubitemid 30000633)
56. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE et al (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CBl receptor. Proc Natl Acad Sci USA 98 (7):3662-3665 (Pubitemid 32249827)
57. Hayn MH, Ballesteros I, de Miguel F, Coyle CH, Tyagi S, Yoshimura N et al (2008) Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology 72(5): 1174-1178
58. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87(5): 1932-1936
59. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA et al (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289(3): 1427-1433 (Pubitemid 29246674)
60. Hiragata S, Ogawa T, Hayashi Y, Tyagi P, Seki S, Nishizawa O et al (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70 (1):202-208 (Pubitemid 47081082)
61. Ho WS, Barrett DA, Randall MD, Ho WSV (2008) 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155(6):837-846
62. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38(1): 1-20
63. Holzer P (2004) TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 500(1-3):231-241
64. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161-202
65. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR et al (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39(20) :3875-3877
66. Huffman JW, Yu S, Liddle J, Wiley JL, Abood M, Martin BR et al (eds) (1999) 1-Deoxy-1-, 1-dimethylalkyl-8-THC derivatives: selective ligands for the CB2 receptor. In: 1999 Symposium on the Cannabinoids 1998. International Cannabinoid Research Society, Acapulco, Mexico, Burlington, Vermont
67. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL et al (1999b) 3-(1′, 1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7(12):2905-2914 (Pubitemid 30105863)
68. Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract, Handb Exp Pharmacol 1.68:573-598
69. Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A et al (2003) An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125(3):765-774 [see comment]
70. Jacobsson SO, Fowler CJ (2001) Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132(8): 1743-1754 (Pubitemid 32397966)
71. Jaggar SI, Sellaturay S, Rice AS (1998a) The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 253(2):123-126 (Pubitemid 28430638)
72. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS (1998b) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76(1-2): 189-199 (Pubitemid 28304956)
73. Jaggar SI, Scott HC, Rice AS (1999) Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent. Br J Anaesthiol 83(3):442-448 (Pubitemid 29412699)
74. Jensen BC. Swigart PM. Simpson PC. Jensen BC. Swigart PM. Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379(4)409-412
75. Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ (2001) Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133(8):1263-1275 (Pubitemid 32783487)
76. Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, Kummer W et al (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379(4):389-395
77. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS et al (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284(43):29817-29827
78. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19(11)4544-4558 (Pubitemid 29241104)
79. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100(4):797-804
80. Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K et al (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39(22)4515-4519 (Pubitemid 26359410)
81. Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6(8):757-773
82. Lambert DM, Vandevoorde S, Diependaele G, Govaerts SJ, Robert AR (2001 ) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42(3) :321-327 (Pubitemid 32275910)
83. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND et al (1999a) Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS Pharmsci 1(2):E4
84. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D et al (1999b) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42(4):769-776 (Pubitemid 29110792)
85. Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoidinduced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276(2):585-593
86. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D et al (1998) Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 41(27):5353-5361 (Pubitemid 29031319)
87. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide, Mol Pharmacol 67(1):15-19 (Pubitemid 40069962)
88. Loria F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangomez M et al (2008) Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 28(4):633-641
89. Lu X, Bartfai T, Lu X, Bartfai T (2009) Analyzing the validity of GaIRl and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol 379(4)417-420
90. Machado Rocha FC, Stefano SC, De Cassia HR, Rosa Oliveira LM, Da Silveira DX, Rosa Oliveira LMQ (2008) Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care 17 (5)431-443
91. Mailleux P, Parmentier M, Vanderhaeghen JJ (1992) Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides, Neurosci Lett 143(1-2):200-204
92. Martin RS, Luong LA, Welsh NJ, Eglen RM, Martin GR, MacLennan SJ (2000) Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol 129(8): 1707-1715 (Pubitemid 30219014)
93. Martyn CN, Illis LS, Thorn J (1995) Nabilone in the treatment of multiple sclerosis. Lancet 345 (8949):579
94. Mascolo N, Izzo AA, Ligresti A, Costagliola A, Pinto L, Cascio MG et al (2002) The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 1.6(14): 1973-1975
95. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561-564 [see comment]
96. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327(4):535-550 (Pubitemid 23033649)
97. Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G et al (2009) Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem 16(5):332-337
98. McMahon SB (1988) Neuronal and behavioural consequences of chemical inflammation of rat urinary bladder. Agents Actions 25(3-4):231-233
99. McMahon SB, Abel C (1987) A model for the study of visceral pain states: chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals. Pain 28(1): 109-127 (Pubitemid 17210463)
100. Mechoulam R, Fride E (2001) Physiology, a hunger for cannabinoids. Nature 410(6830):763 [comment]
101. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83-90
102. Merriam FV, Wang ZY, Guerios SD, Bjorling DE, Merriam FV, Z-y W et al (2008) Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats, Neurosci Lett 445 (1): 130-134
103. Michel MC, Wieland T, Tsujimoto G, Michel MC, Wieland T, Tsujimoto G (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 379 (4):385-388
104. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441):61-65 [see comment]
105. Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I et al (2006) Tricyclic pyrazoles. 4, Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand l-(2′, 4′- dichlorophenyl)-6-methyl-N-piperidin-1-yl-1, 4-dihydroindeno[1, 2-c]pyrazole-3-carboxamide. J Med Chem 49(25):7502-7512
106. Nagy I, Santha P, Jancso G, Urban L, Nagy I, Santha P et al (2004) The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology, Eur J Pharmacol 500(1-3):351-369 (Pubitemid 39304020)
107. Nazif O, Teichman JM, Gebhart GF, Nazif O, Teichman JMH (2007) Neural upregulation in interstitial cystitis. Urology 69(4 Suppl):24-33
108. O'Sullivan SE (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors, Br J Pharmacol 152(5):576-582
109. O'Sullivan SE, Kendall DA, Randall MD, O'Sullivan SE, Kendall DA, Randall MD (2009) Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res 2009:425289
110. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L et al (2008) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci 1139:434-449
111. Pacheco M, Childers SR, Arnold R, Casiano F, Ward SJ (1991) Aminoalkylindoles: actions on specific G-protein-linked receptors. J Pharmacol Exp Ther 257(1):170-183
112. Pertwee RG (2001) Cannabinoids and the gastrointestinal tract. Gut 48(6):859-867
113. Pertwee RG, Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118(8):2053-2058 (Pubitemid 26292576)
114. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD (1992) Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol 105(4):980-984
115. Pertwee RG, Fernando SR, Nash JE, Courts AA (1996) Further evidence for the presence of cannabinoid CBl receptors in guinea-pig small intestine. Br J Pharmacol 118(8):2199-2205 (Pubitemid 26292596)
116. Peters MF, Scott CW, Peters MF, Scott CW (2009) Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen 14(3):246-255
117. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH et al (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch. Pharmacol 379(4):397-402
118. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L et al (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40 (20):3228-3233 (Pubitemid 27413747)
119. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350(2-3):240-244 (Pubitemid 24268029)
120. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C et al (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284(2):644-650 (Pubitemid 28086654)
121. Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178:107-115 [see comment]
122. Rodriguez JJ, Mackie K, Pickel VM (2001) Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21(3):823-833 (Pubitemid 32163123)
123. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126(3):665-672 (Pubitemid 29087845)
124. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J et al (2002) Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301(3):900-907 (Pubitemid 34595078)
125. Sade H, Muraki K, Ohya S, Hatano N, Imaizumi Y, Sade H et al (2006) Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol 290(1): C77-C86
126. Saitoh C, Kitada C, Uchida W, Chancellor MB, de Groat WC, Yoshimura N et al (2007) The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder, Eur J Pharmacol 570(1-3): 182-187 (Pubitemid 47247672)
127. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, Bonnin-Cabanne O et al (1996) Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307(2): 132-136
128. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278(3):989-999 (Pubitemid 27166944)
129. Shu YZ (1998) Recent natural products based drug development: a pharmaceutical industry perspective. J Nat Prod 61 (8):1053-1071
130. Sibley WA (1992) Therapeutic claims in multiple sclerosis, 3rd edn. Demos Medical, New York
131. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI et al (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129 (2):227-230 (Pubitemid 30072640)
132. Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ, Smart D et al (2002) 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136(3)452-458
133. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T et al (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275(1):605-612 (Pubitemid 30039024)
134. Tokanovic S, Malone DT, Ventura S (2007) Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Br J Pharmacol 150(2):227-234 (Pubitemid 46160613)
135. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83(2):393-411 (Pubitemid 28062631)
136. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999) Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93(3):969-975 (Pubitemid 29341643)
137. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB et al (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181(4):1932-1938
138. Ueda N, Yamamoto S (2000) Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat 61(1-2):19-28 (Pubitemid 30216486)
139. Wade DT, Robson P, House H, Makela P, Aram J (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17( 1):21-29 (Pubitemid 36230977)
140. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10(4)434-441 [see comment]
141. Wahn H, Wolf J, Kram F, Frantz S, Wagner JA, Wahn H et al (2005) The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 289(6): H2491-H2496 (Pubitemid 41698562)
142. Walczak JS, Price TJ, Cervero F (2009) Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience 159(3):1154-1163
143. Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S et al (2005) ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells, J Clin Invest 1.15(9):241.2-2422 (Pubitemid 41266203)
144. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63(3):637-652 (Pubitemid 24360219)
145. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362(9395): 1517-1526 [see comment]